Industry
Biotechnology
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Loading...
Open
7.45
Mkt cap
546M
Volume
1.9M
High
7.68
P/E Ratio
-4.71
52-wk high
14.84
Low
7.37
Div yield
N/A
52-wk low
2.31
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 11:05 am
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 2:34 pm
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 2:26 pm
Portfolio Pulse from Vaishali Prayag
June 26, 2024 | 8:18 pm
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 7:26 pm
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 11:34 am
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 2:03 pm
Portfolio Pulse from Adam Eckert
June 24, 2024 | 1:16 pm
Portfolio Pulse from ryanfaloona@benzinga.com
June 24, 2024 | 12:39 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.